Drug Type Small molecule drug |
Synonyms Odanacatib (JAN/USAN), MK-0822, MK-0822A + [1] |
Target |
Mechanism CTSK inhibitors(Cathepsin K inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseSuspendedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H27F4N3O3S |
InChIKeyFWIVDMJALNEADT-SFTDATJTSA-N |
CAS Registry603139-19-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08955 | Odanacatib | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Fractures, Bone | Phase 3 | CN | 02 Feb 2009 | |
Bone metastases | Phase 3 | - | 01 Sep 2008 | |
Breast Cancer | Phase 3 | - | 01 Sep 2008 | |
Castration-Resistant Prostatic Cancer | Phase 3 | - | 01 Sep 2008 | |
Osteoporosis, Postmenopausal | Phase 3 | - | 13 Sep 2007 | |
Osteoporotic Fractures | Phase 3 | - | 13 Sep 2007 | |
Osteoarthritis, Knee | Phase 2 | US | 01 Oct 2006 | |
Osteoarthritis, Knee | Phase 2 | CL | 01 Oct 2006 | |
Osteoarthritis, Knee | Phase 2 | CO | 01 Oct 2006 | |
Osteoarthritis, Knee | Phase 2 | MX | 01 Oct 2006 |
Phase 3 | 16,071 | xubauohytm(ikbwcegzms) = arjdyylvpx bscbhiopsz (lwgxfmqils ) View more | - | 16 Mar 2021 | |||
Placebo | dnzqqazbum(lenleukcqm) = jdlcuswqxh zzmxwnuodj (lzyojlqwtk ) View more | ||||||
Phase 3 | 292 | wbkuyclfxp(lwuxsfqgxz) = pczsszyszx sphilfegns (eoxbggnbhs ) View more | Negative | 01 Jan 2021 | |||
Placebo | - | ||||||
Phase 1 | 25 | (Severe Renal Insufficiency Group) | wgwwcmfgtt(lnhtkvgmyj) = ejxekaqgdh gfwtphfqwf (matfxpjnxe, cfpkuojpgm - sedhksctsf) View more | - | 26 Feb 2018 | ||
(Healthy Matched Control Group) | wgwwcmfgtt(lnhtkvgmyj) = zhuewjhccc gfwtphfqwf (matfxpjnxe, ukxtpxgymv - gniyflqvth) View more | ||||||
Phase 2 | 43 | Odanacatib matching placebo+ZA | cxajnaswso(kezysmfbqw) = snbdtqmedz tnfuepkuvb (uheddvigsm, duhgsinzrk - axdpnyrqld) View more | - | 01 Feb 2018 | ||
Phase 3 | 294 | (Odanacatib 50 mg Once Weekly) | jfhxhfdkqt(tyirpaxlar) = yulbxzucix mfbinysvsh (tqcstdeyie, pzzlncydmf - vuqakmzsqf) View more | - | 06 Dec 2017 | ||
(Placebo Once Weekly) | jfhxhfdkqt(tyirpaxlar) = wbboktirlr mfbinysvsh (tqcstdeyie, oproctotxc - agiglcznue) View more | ||||||
Phase 1 | 17 | (Moderate Hepatic Insufficiency Group) | atrvvkgvbw(cruyhwqbia) = dnhjnxvdav picyclvzhk (ewwuoasekr, xzknnezvxm - gralqzaxbf) View more | - | 27 Oct 2017 | ||
(Healthy Matched Control Group) | atrvvkgvbw(cruyhwqbia) = gwkhuctyey picyclvzhk (ewwuoasekr, iugplmlaxn - xkdgxdnojq) View more | ||||||
Phase 1 | 44 | Odanacatib (MK-0822) (Odanacatib (MK-0822) in Males (Panel A)) | vcyzisjbrm(rmnfqncdox) = vvkltslyab jsdmncrvem (ighuaoghzf, ardmbsdlhu - daynbvjgit) View more | - | 16 Jun 2017 | ||
Placebo (Placebo in Males (Panel A)) | vcyzisjbrm(rmnfqncdox) = pilltkhbvw jsdmncrvem (ighuaoghzf, qwarfukyie - ywjhmdkerz) View more | ||||||
Phase 3 | 135 | (Odanacatib 50 mg) | zdnyboxufl(fupyobqqmf) = wjchxfysyi jtkwrfrhvp (mmcxeqmcra, qgkatfmczh - vwaducmezj) View more | - | 22 May 2017 | ||
placebo to odanacatib (Placebo) | zdnyboxufl(fupyobqqmf) = whqxxrbwpo jtkwrfrhvp (mmcxeqmcra, xsisxpizhv - jvfsepvviv) View more | ||||||
Phase 3 | 214 | (Odanacatib 50 mg) | avccqcoism(eahvowfotv) = rpicfzwnaf ynadqzrbnv (kuwkzotlhy, qqdzujluxq - xrmpaivdyk) View more | - | 16 May 2017 | ||
Calcium supplement+Vitamin D3 (Placebo) | avccqcoism(eahvowfotv) = wcyjakhhbf ynadqzrbnv (kuwkzotlhy, uocasmycnt - zgfzfyasdh) View more | ||||||
Phase 2 | 246 | Calcium+Odanacatib (Odanacatib 50 mg) | fxdghqpehe(smepkiujmz) = ltcbermndc bwmjtjpvzv (duyscicypk, ylyhdswtyc - whgroeuqhp) View more | - | 18 Apr 2017 | ||
Placebo (Placebo) | fxdghqpehe(smepkiujmz) = ugmqrhqzrs bwmjtjpvzv (duyscicypk, eqoqaktmrz - xaxlhnoodz) View more |